Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie | Contract Pharma

What are you searching for?

Sign in
Breaking News

Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

Continues to build integrated capabilities platform for cell and gene therapy.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pharmaron Beijing has entered into a definitive agreement to acquire Allergan Biologics Limited (ABL) in Liverpool, UK, for $118.7 million from AbbVie. The transaction is expected to close in the second quarter of 2021, subject to the satisfaction of customary closing conditions.

The ABL site consists of a state-of-the-art, flexible cGMP biomanufacturing facility located in Liverpool with over 150 staff. Leveraging the industry-leading expertise in the process R&D, cGMP manufacturing and advanced analytical capabilities in broad range of biologics products, the ABL site has further established a solid foundation and expertise in cell and gene therapy (CGT) product development using a suspension system for manufacturing up to commercial scale. The ABL site has held MHRA biologic manufacturing license accreditation since 2007.

This transaction will be highly synergistic to Pharmaron’s recent acquisition of Absorption Systems in the U.S. for building an integrated CGT services platform. This integrated platform, which offers preclinical research, product development, and commercial manufacturing services for CGT products, provides unparalleled value proposition to our partners in this rapidly growing field of innovative therapies.

“We are pleased to have the ABL site join the Pharmaron Group,” said Boliang Lou, chairman and chief executive officer, Pharmaron. “We have been impressed with the CGT focused process R&D and complex biologic manufacturing capabilities of the ABL site, as well as the abilities that the highly experienced scientific, technical and managerial teams have demonstrated.

“The addition of this platform to Pharmaron will further strengthen our CGT services platform and allow us to better serve our partners’ needs in these exciting and emerging therapies.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics